



Precision Treatment in ACS–Role of Assessing Fibrinolysis
Ying X. Gue 1,2, Young-Hoon Jeong 3 , Mohamed Farag 2, Nikolaos Spinthakis 2 and Diana A. Gorog 2,4,*


Citation: Gue, Y.X.; Jeong, Y.-H.;
Farag, M.; Spinthakis, N.; Gorog, D.A.
Precision Treatment in ACS–Role of
Assessing Fibrinolysis. J. Clin. Med.
2021, 10, 929. https://doi.org/
10.3390/jcm10050929
Academic Editor: Eliano Navarese
Received: 29 January 2021
Accepted: 18 February 2021
Published: 1 March 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital,
Liverpool L14 3PE, UK; y.gue@liverpool.ac.uk
2 Department of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK;
mohamedfarag@nhs.net (M.F.); nspinthakis@nhs.net (N.S.)
3 Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular
Center, Gyeongsang National University Changwon Hospital, Changwon 51472, Korea;
goodoctor@naver.com
4 National Heart and Lung Institute, Imperial College, London SW3 6LY, UK
* Correspondence: d.gorog@imperial.ac.uk
Abstract: Despite advancements in pharmacotherapy and interventional strategies, patients with
acute coronary syndrome (ACS) remain at risk of recurrent thrombotic events. In addition to an
enhanced tendency to thrombus formation, impairment in the ability to naturally dissolve or lyse
a developing thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part
of this residual risk regardless of optimal antiplatelet medication. Global assessment of endoge-
nous fibrinolysis, including a point-of-care assay, can identify patients with ACS at persistent high
cardiovascular risk and might play an important role in allowing the personalisation of potent an-
tithrombotic therapy to enhance fibrinolytic status, providing precision treatment of ACS to improve
long-term outcome.
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1. Background
The mainstay management of acute coronary syndrome (ACS) involves the use of
antithrombotic therapy to reduce the risk of adverse ischaemic events [1]. International
guidelines for antithrombotic treatment for ACS patients recommend administration of
dual antiplatelet therapy (DAPT), comprising of aspirin together with a P2Y12 inhibitor [2,3].
However, despite advancements in pharmacotherapy and interventional strategies, ap-
proximately 10% of ACS patients remain at risk of major adverse cardiovascular events
(MACE) after an ACS, a risk mainly driven by thrombotic events [4,5]. This was initially
attributed to reduced antiplatelet effect with high on-treatment platelet reactivity (HTPR),
potentially due to variability of individual responsiveness to antiplatelet agents [6]. How-
ever, although there appeared to be a correlation between observed HTPR and adverse
events [7], randomised studies utilising platelet function test (PFT) to guide management
have not significantly improved clinical outcomes [8,9]. The TRILOGY ACS (Targeted
Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary
Syndromes) PFT (VerifyNow P2Y12 assay) sub-study showed that even with a more potent
P2Y12 inhibitor like prasugrel, which resulted in lower platelet reactivity when compared
to clopidogrel (median 64; interquartile range (IQR), 33–128 P2Y12 reaction unit (PRU) vs.
200; IQR, 141–260 PRU; p < 0.001), there was no significant difference in clinical outcomes
(cardiovascular death, myocardial infarction and stroke) at 30 months (17.2% vs. 18.9%,
p = 0.29). This shows that the residual ischemic risk in these high-risk patients cannot be
simply explained by HTPR [5].
Haemostasis is a complex sequence of biochemical responses to injury, which facilitates
formation of a blood clot and reparation of the damaged endothelium. The maintenance of
the equilibrium between coagulation and fibrinolysis is critical to health, as any imbalance
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may lead to either abnormal bleeding, resulting in haemorrhage, or thrombosis resulting
in ischemia. Attempts to manage and prevent thrombotic events have mainly focused
on preventing the formation of a thrombus—namely with the use of antiplatelet and/or
anticoagulant agents. Whilst treatment with DAPT addresses the enhanced platelet reac-
tivity in ACS, ongoing activation of the coagulation cascade and impaired endogenous
fibrinolysis appears to be unaffected by the current DAPT strategy [10].
In addition to the activation of coagulation, the inflammatory pathway has been
identified to contribute to the residual ischemic risk in patients with atherosclerotic dis-
ease [11]. The CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study)
included stabilized myocardial infarction (MI) patients with persistent high inflammatory
risk (high-sensitivity C-reactive protein ≥2 mg/L) treated with canakinumab, a mono-
clonal antibody targeting interleukin-1β, demonstrated a significant reduction in MACE
with canakinumab compared with patients received placebo (hazard ratio (HR) 0.85, 95%
confidence interval (CI), 0.74 to 0.98; p = 0.021) [12]. Indeed, both the inflammation and
coagulation pathways contribute to the ischemic risk and there has been increasing evi-
dence of cross-over between the two pathways (i.e., inflammation leads to activation of
coagulation, and coagulation considerably impacts on the inflammatory activity) [13,14].
Furthermore, and apart from the increased tendency to thrombus formation (enhanced
platelet reactivity), impairment in the ability to naturally dissolve or lyse a developing
thrombus, namely impaired endogenous fibrinolysis, is responsible for a major part of the
remaining residual risk in patients with ACS on optimal antiplatelet medication [15].
2. Assessment of Fibrinolysis
2.1. Assessment of Individual Enzymes and Proteins That Mediate Fibrinolysis
The role of impaired endogenous fibrinolysis in ACS is well recognized [16,17]. Several
biomarkers, namely factors regulating fibrinolysis (such as tissue plasminogen activator
(t-PA), plasminogen activator inhibitor 1 (PAI-1), and lipoprotein A (Lp(a))) have been
investigated in various studies. A higher level of t-PA correlated with an increased risk
of MACE post-ACS [18]. Moreover, patients with ACS exhibited higher t-PA levels when
compared to patients with stable angina [19]. PAI-1 levels independently predicted in-
hospital and one-year mortality in patients with ACS [20], and their increased levels were
associated with higher rates of all-cause mortality and MI [21]. However, these results were
not observed in other studies [22,23]. Similarly with Lp(a), previous studies have shown
weak correlations [22] whereas more recent studies have not shown any association of Lp(a)
level and mortality [24]. These conflicting results show the complexity of assessing the
fibrinolytic activity using individual enzymes and proteins [16] and hence are of limited
utility in advancing personalised medicine.
2.2. Global Assessment of Lysis
2.2.1. Turbidimetric Clot Lysis Assay
As the structure of the fibrin network regulates the mechanical stability of the throm-
bus and its resistance to fibrinolysis, the assessment of fibrin clot structure can provide
information about thromboembolic risk and susceptibility to lysis [25]. Turbidimetric lysis
analysis uses citrated plasma to which agonists added—a calcium/thrombin buffer—to
induce clot formation, and t-PA added to induce fibrinolysis. Fibrin clot lysis is the measure
of time to achieve lysis of the clot and typically the speed at which 50% lysis occurs, as
well as maximal absorbance, are measured. Assessment of fibrinolysis with plasma clot
lysis has been shown to independently predict recurrent MI and cardiovascular death
in all-comers following ACS [26] and also specifically in ACS patients with diabetes [27].
However, the use of plasma rather than whole blood, means that the impact of cellular
constituents of blood on lysis is not assessed. Furthermore, the addition of agonists and
t-PA to induce thrombosis and fibrinolysis means that in fact, this technique detects the
plasma’s ability to respond to external fibrinolytic treatment, as opposed to measuring en-
dogenous, native fibrinolysis. Additionally, the test is cumbersome and requires dedicated
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and experienced laboratory staff trained to perform this reliably, making it impracticable in
the clinical setting.
2.2.2. Thromboelastography and Thromboelastometry
Thromboelastography (TEG®: Haemonetics, UK) and rotational thromboelastome-
try (ROTEM®: Pentapharm GmbH, Munich, Germany) are point-of-care, global tests of
coagulation status, simultaneously assessing clot development, stabilization, and dissolu-
tion/lysis, both based on the same principles. These techniques utilize a pin suspended by
a torsion wire into a cylinder to measure the physical properties of a clot. As blood clot
formation occurs around the pin, fibrin strands form between the cylindrical cup and pin.
The rotation of the cylindrical cup is transmitted to the pin, whose displacement is then
picked up by the torsion wire. This is analysed and presented in graphical form by the
instrument to allow analysis of different stages of coagulation and fibrinolysis [28]. The
technique is able to measure clot formation time and rate, maximum amplitude or clot
strength and clot lysis time. TEG can be performed using native blood sample or with
modification such as with the addition of urokinase [29] which can improve detection of
fibrinolysis but this has only been performed in patients with sepsis [30] and may therefore
be of lesser clinical relevance in the ACS setting. More recently, the ClotPro® (enicor GmbH,
Munich, Germany) which utilizes viscoelastic principles but allows the use of manufacturer
provided reagents to test different aspects of the coagulation pathway could bring about
more clinical uses [31].
TEG is well-established in detecting hyperfibrinolysis, namely bleeding risk, but its
success is limited in the assessment of hypofibrinolysis or thrombosis risk [32,33]. Another
TEG shortcoming is the employment of the low-flow, static-type conditions, which resemble
more venous rather than arterial thrombosis. This is less reflective of the physiological
response to high shear thrombosis that occurs in ACS.
2.2.3. Global Thrombosis Test
The global thrombosis test (GTT; Thromboquest Ltd., London, UK) is an automated,
point-of-care test that simultaneously assesses platelet reactivity, thrombosis, and fibri-
nolytic activity, from a native whole blood sample subjected to high shear [34]. Blood
inserted into the instrument’s cartridge passes through a plastic conical tube where narrow
gaps create high shear stress that mimics flow within a narrowed vessel, activating platelets
and inducing occlusive thrombus formation. Thrombus formation gradually reduces and
finally occludes flow in the cartridge. Arrest of flow, as detected by an optical sensor, is
expressed as occlusion time (OT). Blood flow resumes following spontaneous fibrinolysis,
and the time taken to do so is expressed as lysis time (LT). The GTT therefore provides a
comprehensive evaluation of thrombosis and lysis under high shear stress.
The main advantage of GTT is that it is an easy-to-use point-of-care test that mimics
arterial thrombosis and can assess platelet reactivity, thrombus stability and endogenous
fibrinolysis, providing an overall global assessment. The use of native, non-anticoagulated
whole blood allows the measurement of the effects of thrombin generation in platelet
aggregation without depletion of calcium (as opposed to citrated blood which is commonly
required in other tests). Secondly, the presence of high shear as the key initiator of platelet
activation is analogous to the physiological mechanism of platelet activation within a
stenosed artery. Lastly, the assessment of spontaneous lysis through the measurement
of LT is comparable to the physiological recanalization of an occluded artery. The main
disadvantage is the requirement of immediate analysis of the native blood sample, which
means samples cannot be stored for subsequent analysis.
3. Impaired Endogenous Fibrinolysis and Cardiovascular Risk
Several avenues of observational studies indicate that impaired endogenous fibri-
nolysis is associated with adverse outcomes. Of note, unfavourable fibrin clot properties
that render fibrin clots more resistant to lysis are correlated with prothrombotic charac-
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teristics such as hypertension, diabetes, hyperlipidemia and smoking [35]. There has
been increasing evidence that impaired endogenous fibrinolysis is a strong predictor of
residual thrombotic risk in patients with ACS. In the RISK PPCI study, involving nearly
500 patients with ST-segment elevation MI, impaired endogenous fibrinolysis as measured
using GTT, was detected in 14% of patients on admission and was strongly related to
recurrent MACE (HR 9.1, 95% CI 4.28–15.03, p = 0.001), driven by cardiovascular death
and MI [10]. In a different cohort of 300 ACS patients, impaired endogenous fibrinolysis
was associated with an increased risk of MACE at 12 months (HR 2.52, 95% CI 1.34–4.71,
p = 0.004) [36]. These studies provide a link between impaired endogenous fibrinolysis
and residual cardiovascular risk. Furthermore, ACS patients with impaired fibrinolysis
were shown to produce in vitro clots that, under electron microscopy, comprised of more
highly branched, denser fibrin meshwork than patients with effective lysis potential [37].
In a sub-study of >4000 patients in the PLATO (Study of Platelet Inhibition and Patient
Outcomes) trial, assessment of plasma clot lysis using a turbidimetric assay revealed that
impaired fibrin clot lysis was an independent predictor of adverse outcome in ACS [26].
After adjusting for established cardiovascular risk factors, each 50% increase in lysis time
was associated with cardiovascular death/spontaneous MI (HR 1.17, 95% CI 1.05–1.31;
p < 0.01) and cardiovascular death alone (HR 1.36, 95% CI 1.17–1.59; p < 0.001). Similarly,
in the sub-study involving diabetic patients, after adjusting for cardiovascular risk factors,
each 50% increase in lysis time was associated with increased risk of cardiovascular death
or MI (HR 1.21; 95% CI 1.02–1.44; p = 0.026) and cardiovascular death alone (HR 1.38; 95%
CI 1.08–1.76; p = 0.01) [27].
These studies point towards the potential of using the assessment of endogenous
fibrinolysis as a biomarker to identify patients who may be at increased risk of future
adverse thrombotic events. This could allow the use of more potent antithrombotic phar-
macotherapy in these patients to reduce the thrombotic risk.
4. ACS Risk Stratification Based on Fibrinolysis Assessment
The role of risk stratification in ACS patients is not new. There are various ways of
stratifying ACS patients including the use of risk scores to determine patients who may be
suitable for outpatient investigations and treatment [38], early aggressive treatment [39]
and duration of antithrombotic therapy [40]. Many of these risk scores make use of clinical
characteristics such as age and co-morbidities, which are commonly overlapping in both
thrombotic and bleeding risks, therefore have limited use in accurately risk stratifying
patients into high- versus low-risk in either bleeding or thrombotic risk. Biomarkers such
as cardiac troponins assess short-term cardiovascular risk, but are not helpful beyond the
acute hospitalisation and do not influence the choice of pharmacotherapy to reduce the
thrombotic risk or personalise treatment.
The assessment of endogenous fibrinolysis may allow for personalised and targeted
therapy whereby patients who are identified as having impaired endogenous fibrinolysis
(higher thrombotic risk compared to bleeding risk) could be offered more potent phar-
macotherapy to enhance fibrinolysis to reduce ischaemic cardiovascular events, while
accepting a potential increased bleeding risk, in favour of an overall favourable risk-to-
benefit ratio in high-risk individuals. Similarly, perhaps those who are identified as having
enhanced endogenous fibrinolysis could be offered less potent pharmacotherapy to reduce
the potential risk for bleeding. This strategy may allow ACS patients to gain the net benefit
and reduce the overall risk of future complications.
5. Pharmacological Modulation of Endogenous Fibrinolysis
Unlike the enhanced platelet reactivity in ACS patients which improves in response
to antiplatelet therapy, impaired fibrinolysis in ACS patients appears to be unaffected by
DAPT [10,26].
A previous study assessing the effect of different P2Y12 inhibitors (oral clopidogrel,
ticagrelor and intravenous cangrelor) on endogenous fibrinolysis in patients with coronary
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artery disease found that although all drugs reduced platelet reactivity, only cangrelor
enhanced fibrinolysis, potentially through thrombus destabilization [41]. However, in
2 different studies exploring the effect of oral anticoagulants (OAC) on endogenous fibri-
nolysis in patients with atrial fibrillation, all OACs showed a signal towards enhancing
endogenous fibrinolysis although only apixaban achieved a significant improvement in
lysis [42,43]. It remains to be investigated whether the combination of antiplatelets and
oral anticoagulants further enhances endogenous fibrinolysis.
6. The Effect of Anticoagulation on Cardiovascular Risk
There is evidence for activation of the coagulation cascade in patients presenting with
ACS with elevation of biomarkers of coagulation activation including increased levels of
d-dimer [44] and fibrinogen [45]. The link between higher d-dimer levels and the risk of
subsequent stent thrombosis indirectly supports the theory of an enhanced coagulation
cascade driving residual risk [16]. Furthermore, there is evidence that use of oral antico-
agulation in patients with established cardiovascular disease reduces cardiovascular risk.
Addition of warfarin to antiplatelet therapy in patients with ACS achieved a reduction in
thrombotic events and death (16.7% vs. 20%, 95% CI 0.69–0.95, p = 0.03) but at the expense
of increased bleeding (4.9% vs. 1.7%, p < 0.001) [46]. Furthermore, in the ATLAS ACS-TIMI
51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy
in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51)
study, the addition of rivaroxaban 2.5 mg b.i.d. to DAPT in patients with a recent ACS
resulted in a reduction in cardiovascular mortality (2.7% vs. 4.1%, p = 0.002), but also at the
expense of major bleeding (2.1% vs. 0.6%, p < 0.001) and intracranial haemorrhage (0.6%
vs. 0.2%, p = 0.009) [47]. In the COMPASS (Cardiovascular Outcomes for People Using
Anticoagulation Strategies) study, among patients with stable atherosclerotic vascular
disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had fewer adverse
cardiovascular outcomes, comprising of cardiovascular death, MI and stroke, than those
assigned to aspirin alone, but with an increase in bleeding risk [48].
It is possible that the reduction in ischaemic events with OAC is achieved through
enhancing endogenous fibrinolysis. Therefore, whilst OAC is clearly not be suitable for
all patients, in order to achieve maximum net clinical benefit, ACS risk stratification to
identify patients at higher ischemic risk is pertinent. The ongoing VaLiDate-R (can very
low dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic
status in acute coronary syndrome?) study [49] (ClinicalTrials.gov Identifier: NCT03775746,
EudraCT: 2018-003299-11) aims to assess whether the addition of vascular dose rivaroxaban
can favourably enhance endogenous fibrinolysis in patients with recent ACS.
7. Precision Treatment in ACS Based on Fibrinolytic Status
Apart from the potential as a risk stratification tool in ACS, the assessment of en-
dogenous fibrinolysis could enable personalised “precision” medicine in these patients
(Figure 1). Patients at high ischemic risk, as determined by markedly impaired fibrinolysis,
may derive the greatest benefit from use of more potent antithrombotic therapy than is
conventionally employed, for example by addition of OAC to antiplatelet therapy. On
the other hand, patients at low ischemic risk could avoid the increased risk of bleeding
complications and may benefit from de-escalation of the intensity of antithrombotic therapy.
Being able to risk stratify patients would empower clinicians to decide on the optimal phar-
macotherapy to achieve the net clinical benefit, by balancing the risks of thrombosis and
bleeding in a particular individual. Point-of-care testing of fibrinolytic status could facilitate
the assessment of future ischaemic risk and allow timely monitoring and personalisation
of pharmacotherapy.
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